Summary

Global Etoricoxib Market was valued at USD 110.78 million in 2024 and is projected to reach USD 271.44 million by 2030, growing at a compound annual growth rate (CAGR) of 12.06% during the forecast period. This market is experiencing consistent growth, primarily driven by the rising demand for effective anti-inflammatory treatments and the increasing prevalence of conditions such as osteoarthritis, rheumatoid arthritis, and chronic pain disorders.
Etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is widely used for the management of pain and inflammation associated with these medical conditions. As a nonsteroidal anti-inflammatory drug (NSAID), it is preferred due to its targeted mechanism of action, which reduces the likelihood of gastrointestinal side effects typically associated with conventional NSAIDs. By selectively inhibiting COX-2 rather than COX-1, etoricoxib offers a more precise approach to pain and inflammation management. This pharmacological advantage makes it particularly suitable for long-term use, especially among elderly patients or those with a history of gastrointestinal complications. Its favorable safety profile continues to drive adoption among both healthcare professionals and patients.
Key Market Drivers
Growth of the Global Healthcare Industry
The global expansion of the healthcare sector is a significant factor contributing to the increased demand for etoricoxib. As a selective COX-2 inhibitor, etoricoxib is widely recognized for its analgesic and anti-inflammatory properties. The healthcare industry, one of the fastest-growing economic sectors worldwide, accounts for more than 10% of GDP in many developed economies. For instance, healthcare spending in the United States rose by 2.7% in 2021, reaching USD 4.3 trillion, or approximately USD 12,914 per capita.
With ongoing improvements and expansion in healthcare systems—particularly across emerging markets—the demand for effective pain management solutions has surged. Etoricoxib’s ability to treat chronic conditions such as osteoarthritis, rheumatoid arthritis, and acute pain positions it as a valuable addition to modern, patient-centered treatment plans.
Key Market Challenges
Supply Chain Vulnerabilities
The production of etoricoxib depends on the availability of pharmaceutical-grade raw materials and intermediate compounds. Disruptions in the supply chain—whether due to bottlenecks, regulatory restrictions, or volatility in raw material prices—can significantly delay manufacturing and impact product availability. For example, shortages or cost increases in essential inputs may lead to elevated production costs, reducing profit margins or resulting in higher prices for end-users.
Geopolitical factors such as trade disputes, tariffs, and regional instability further complicate global supply chains. Given that etoricoxib manufacturers typically depend on a network of international suppliers and contract manufacturers, any disruption—whether due to customs delays, export restrictions, or geopolitical conflict—poses a substantial risk. These challenges are particularly critical in the pharmaceutical industry, where timely access to medications is essential for patient care.
Key Market Trends
Emphasis on Targeted Pain Relief
A growing trend in the global etoricoxib market is the increasing emphasis on targeted pain management, especially in the context of chronic pain and inflammation. Etoricoxib, as a selective COX-2 inhibitor, is approved for short-term relief of moderate post-operative dental pain and for treating pain and inflammation associated with various forms of arthritis.
With the healthcare industry shifting toward precision medicine, there is a heightened focus on therapies that provide safer, more personalized, and more effective treatment outcomes. Etoricoxib is gaining traction due to its ability to precisely target pain and inflammatory pathways while minimizing the adverse effects typically linked to traditional NSAIDs.
Unlike non-selective NSAIDs that inhibit both COX-1 and COX-2 enzymes, etoricoxib’s selective inhibition of COX-2 is associated with a lower risk of gastrointestinal and cardiovascular complications. This makes it an attractive option for long-term pain management, particularly in older adults and patients with preexisting health conditions.
Key Market Players
• Orex Pharma
• Aurore Life Sciences
• Hetero
• Aoki Medicinal
• Guangdong Raffles Pharma Tech Co.,Ltd
• Sichuan Yujian Pharmaceutical Co., Ltd
• Gennex Laboratories Limited
• Cipla Limited
• MICRO LABS LIMITED
• Greenkem Organics Pvt Ltd
Report Scope
In this report, the Global Etoricoxib Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Etoricoxib Market, By Sales Channel:
o Direct
o Indirect
• Etoricoxib Market, By End Use:
o Osteoarthritis
o Rheumatoid Arthritis
o Ankylosing Spondylitis
o Acute Gouty Arthritis
o Others
• Etoricoxib Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Etoricoxib Market.
Available Customizations:
Global Etoricoxib Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Impact of COVID-19 on Global Etoricoxib Market
5. Global Etoricoxib Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Sales Channel (Direct, Indirect)
5.2.2. By End Use (Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Acute Gouty Arthritis, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Etoricoxib Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Sales Channel
6.2.2. By End Use
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Etoricoxib Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Sales Channel
6.3.1.2.2. By End Use
6.3.2. Mexico Etoricoxib Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Sales Channel
6.3.2.2.2. By End Use
6.3.3. Canada Etoricoxib Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Sales Channel
6.3.3.2.2. By End Use
7. Europe Etoricoxib Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Sales Channel
7.2.2. By End Use
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Etoricoxib Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Sales Channel
7.3.1.2.2. By End Use
7.3.2. Germany Etoricoxib Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Sales Channel
7.3.2.2.2. By End Use
7.3.3. United Kingdom Etoricoxib Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Sales Channel
7.3.3.2.2. By End Use
7.3.4. Italy Etoricoxib Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Sales Channel
7.3.4.2.2. By End Use
7.3.5. Spain Etoricoxib Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Sales Channel
7.3.5.2.2. By End Use
8. Asia Pacific Etoricoxib Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Sales Channel
8.2.2. By End Use
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Etoricoxib Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Sales Channel
8.3.1.2.2. By End Use
8.3.2. India Etoricoxib Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Sales Channel
8.3.2.2.2. By End Use
8.3.3. South Korea Etoricoxib Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Sales Channel
8.3.3.2.2. By End Use
8.3.4. Japan Etoricoxib Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Sales Channel
8.3.4.2.2. By End Use
8.3.5. Australia Etoricoxib Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Sales Channel
8.3.5.2.2. By End Use
9. South America Etoricoxib Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Sales Channel
9.2.2. By End Use
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Etoricoxib Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Sales Channel
9.3.1.2.2. By End Use
9.3.2. Argentina Etoricoxib Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Sales Channel
9.3.2.2.2. By End Use
9.3.3. Colombia Etoricoxib Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Sales Channel
9.3.3.2.2. By End Use
10. Middle East and Africa Etoricoxib Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Sales Channel
10.2.2. By End Use
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Etoricoxib Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Sales Channel
10.3.1.2.2. By End Use
10.3.2. Saudi Arabia Etoricoxib Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Sales Channel
10.3.2.2.2. By End Use
10.3.3. UAE Etoricoxib Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Sales Channel
10.3.3.2.2. By End Use
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Etoricoxib Market: SWOT Analysis
14. Porters Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Orex Pharma
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. Aurore Life Sciences
15.3. Hetero
15.4. Aoki Medicinal
15.5. Guangdong Raffles Pharma Tech Co.,Ltd
15.6. Sichuan Yujian Pharmaceutical Co., Ltd
15.7. Gennex Laboratories Limited
15.8. Cipla Limited
15.9. MICRO LABS LIMITED
15.10. Greenkem Organics Pvt Ltd
16. Strategic Recommendations
17. About Us & Disclaimer